title: Assessment of chemokine serum levels in epithelial ovarian cancer patients.
abstract: OBJECTIVE
  The study was undertaken to investigate CCL2/MCP-1, CCL3/ MIP-1α, CCL4/MIP-1β, CCL5/RANTES and CXCL8/IL-8 women with epithelial ovarian cancer.
  
  
  METHODS
  Sixteen patients diagnosed with epithelial ovarian cancer and 18 healthy women with no evidence of malign neoplasia (control group) aged from 23 to 89 years (mean ± SEM, 58.7 ± 2.3) were included. The epithelial ovarian cancer patients underwent laparotomy and debulking surgery. Chemokines serum levels were measured by cytometric bead array. Statistical analysis was performed using Mann-Whitney and Kendall's tau. P <0.05 was considered statistically significant for all analyses.
  
  
  RESULTS
  The tumor staging (FIGO) was classified into: I in 4 cases (25%), III in 5 cases (31.3%) and stage IV in 7 cases (43.8%). Sera chemokine dosages of CCL2/MCP-1 and CCL4/MIP-1β were lower in epithelial ovarian cancer patients than in the control group (P = 0.021 and P = 0.030, respectively). No significant difference between groups was observed in the levels of CCL3/MIP-1α, CCL5/RANTES and CXCL8/IL-8. No association between the chemokines analyzed and tumor stage was found. The serum level of CCL4/MIP-1β was correlated with CA-125.
  
  
  CONCLUSIONS
  The study of serum levels of CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES and CXCL8/IL-8 chemokines in epithelial ovarian cancer patients identified a down-regulation in CCL2/MCP-1 and CCL4/MIP-1β, which suggests that the two chemokines may play an important role in the pathophysiology of ovarian cancer.
authors: João Oscar Almeida
authors: JO
authors: Falcão-Júnior
authors: Andréa
authors: A
authors: Teixeira-Carvalho
authors: Eduardo Batista
authors: EB
authors: Cândido
authors: Elisa Lopes
authors: EL
authors: Lages
authors: Gustavo
authors: G
authors: Ferreira Freitas G
authors: Rívia Mara
authors: RM
authors: Lamaita
authors: Lívia Paula
authors: LP
authors: Freire Bonfim
authors: Rafael
authors: R
authors: Borges Salera
authors: Paulo
authors: P
authors: Traiman P
authors: Agnaldo Lopes
authors: AL
authors: da Silva-Filho
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D000077216:Carcinoma, Ovarian Epithelial; D018932:Chemokine CCL2 / Q000097:blood; D054405:Chemokine CCL3 / Q000097:blood; D054407:Chemokine CCL4 / Q000097:blood; D018946:Chemokine CCL5 / Q000097:blood; D018925:Chemokines / Q000097:blood*; D005260:Female; D006801:Humans; D016209:Interleukin-8 / Q000097:blood; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood* / Q000473:pathology* / Q000503:physiopathology; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology* / Q000503:physiopathology
chemical_list: D014408:Biomarkers, Tumor; C111835:CCL2 protein, human; C515429:CCL3 protein, human; C066507:CCL4 protein, human; C483024:CCL5 protein, human; C508606:CXCL8 protein, human; D018932:Chemokine CCL2; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D018925:Chemokines; D016209:Interleukin-8